Details for New Drug Application (NDA): 206011
✉ Email this page to a colleague
NDA 206011 describes ATRACURIUM BESYLATE, which is a drug marketed by Baxter Hlthcare, Baxter Hlthcare Corp, Eugia Pharma, Hikma, Hospira, Hospira Inc, Meitheal, Norvium Bioscience, Teva Parenteral, Watson Pharms Teva, and Watson Labs Inc, and is included in twenty-two NDAs. It is available from three suppliers. Additional details are available on the ATRACURIUM BESYLATE profile page.
The generic ingredient in ATRACURIUM BESYLATE is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.
The generic ingredient in ATRACURIUM BESYLATE is atracurium besylate. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the atracurium besylate profile page.
Summary for 206011
| Tradename: | ATRACURIUM BESYLATE |
| Applicant: | Eugia Pharma |
| Ingredient: | atracurium besylate |
| Patents: | 0 |
Pharmacology for NDA: 206011
| Physiological Effect | Neuromuscular Nondepolarizing Blockade |
Medical Subject Heading (MeSH) Categories for 206011
Suppliers and Packaging for NDA: 206011
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ATRACURIUM BESYLATE | atracurium besylate | INJECTABLE;INJECTION | 206011 | ANDA | AuroMedics Pharma LLC | 55150-217 | 55150-217-10 | 10 VIAL, MULTI-DOSE in 1 CARTON (55150-217-10) / 10 mL in 1 VIAL, MULTI-DOSE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INJECTION | Strength | 10MG/ML | ||||
| Approval Date: | Apr 8, 2015 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
